Retuximab, Ecalismab and Methotrexe

Enow: I appreciate your asking me to join you to talk about this work, which is really the combined effort of 15 neuralogi with a special interest in my cenographis management. And these neurologists represent ten countries. So here we are. Another big up date that was covered by the group was the recommendation on the use of three medications, because you've had new medications become available. Can you tell us what those recommendations are? Enow: Some of them show positive results, others don't.